Literature DB >> 32988708

Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis.

Qing-Song Xie1, Zi-Xiang Chen1, Yi-Jun Zhao1, Heng Gu1, Xiao-Ping Geng1, Fu-Bao Liu2.   

Abstract

Long-term overall survival (OS) after liver resection for non-cirrhotic hepatocellular carcinoma (NCHCC) has been reported recently. The aim of this study was to review outcomes systematically and analyze risk factors for survival after surgical resection for HCC without cirrhosis. A literature search was performed of the PubMed and Embase databases for papers published between January 1995 and October 2012, which focused on hepatic resection for HCC without underlying cirrhosis. Cochrane systematic review methodology was used for this review. Outcomes were OS, operative mortality and disease-free survival (DFS). Pooled hazard ratios (HR) were calculated using the random effects model for parameters considered as potential prognostic factors. Totally, 26 retrospective case series were eligible for inclusion. The 1-, 3- and 5-year OS rate after surgical resection of NCHCC ranged from 62% to 100%, 46.3%-78.0%, and 30%-64%, respectively. The corresponding DFS rates ranged from 48.7% to 84%, 31.0%-66.0%, and 24.0%-58.0%, respectively. Five variables were related to poor survival: multiple tumors (HR 1.68, 95%CI 1.25-2.11); larger tumor size (HR 2.66, 95%CI 1.69-3.63); non-clear resection margin (R0 resection) (HR 3.52, 95%CI 1.63-5.42); poor tumor stage (HR 2.61, 95%CI 1.64-3.58); and invasion of the lymphatic vessels (HR 4.85, 95%CI 2.67-7.02). In sum, hepatic resection provides excellent OS rates for patients with NCHCC, and results have tended to improve recently. Risk factors for poor prognosis comprise multiple tumors, lager tumor size, non-R0 resection and invasion of the lymphatic vessels.
Copyright © 2020. Published by Elsevier Taiwan LLC.

Entities:  

Keywords:  HCC; Liver resection; Meta-analysis; Non-cirrhosis; Systematic review

Mesh:

Year:  2020        PMID: 32988708     DOI: 10.1016/j.asjsur.2020.08.019

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  5 in total

1.  Comparison of portal and capsular microscopic vascular invasion in the outcomes of early HCC after curative resection.

Authors:  Ding-Sen Huang; Ting-Ting Liu; Wei-Ting Lu; Chih-Chi Wang; Chih-Che Lin; Chee-Chen Yong; Kuang-Den Chen; Yueh-Wei Liu; Yuan-Hung Kuo; Yi-Hao Yen; Tsung-Hui Hu; Ming-Chao Tsai
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

2.  The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.

Authors:  Qiao Ke; Fuli Xin; Huipeng Fang; Yongyi Zeng; Lei Wang; Jingfeng Liu
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

Review 3.  Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment.

Authors:  Dimitrios Papaconstantinou; Diamantis I Tsilimigras; Timothy M Pawlik
Journal:  J Hepatocell Carcinoma       Date:  2022-09-03

4.  Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver-A Single Centre Study.

Authors:  Lea Penzkofer; Jens Mittler; Stefan Heinrich; Nicolas Wachter; Beate K Straub; Roman Kloeckner; Fabian Stoehr; Simon Johannes Gairing; Fabian Bartsch; Hauke Lang
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

Review 5.  Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements.

Authors:  Abhilash Perisetti; Hemant Goyal; Rachana Yendala; Ragesh B Thandassery; Emmanouil Giorgakis
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.